(6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid
• 英文别名: (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid
• 化学式: C₂₅H₃₆O₃
• 分子量: 384.559
• InChiKey: HRENHPHNOHLZPF-LEWJYISDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(3,5-dimethoxyphenyl)-2-methylpropanal 在 selenium(IV) oxide 、 sodium chlorite 、 potassium dihydrogenphosphate 、 palladium 10% on activated carbon 、 氨 、 氢气 、 三溴化硼 、 lithium 、 potassium carbonate 、 对甲苯磺酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 、 乙腈 、 叔丁醇 为溶剂， -78.0~90.0 ℃ 、101.33 kPa 条件下， 反应 79.08h， 生成 (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid
  参考文献：
  名称：

  [EN] CANNABINOIDS AND USES THEREOF
  [FR] CANNABINOÏDES ET LEURS UTILISATIONS

  摘要：

  该发明涉及大麻素化合物、包括一个或多个大麻素化合物的药物组合物，以及利用包括一个或多个大麻素化合物的药物组合物治疗患有疾病或症状（例如，纤维化疾病或炎症性疾病）的患者的用途。

  公开号：

  WO2019232413A1

文献信息

• Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20050085478A1

  公开（公告）日：2005-04-21

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a low-molecular-weight heparin in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了治疗受试者中枢神经系统损伤的组合物和方法。更具体地说，本发明提供了一种治疗中枢神经系统缺血性疾病或中枢神经系统创伤性损伤的组合疗法，包括向受试者施用低分子量肝素与环氧化酶-2 选择性抑制剂。
• Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
  申请人：Arneric P. Stephen

  公开号：US20050085479A1

  公开（公告）日：2005-04-21

  The present invention provides compositions and methods for the treatment of ischemic mediated central nervous system disorder or injury. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist or a pharmaceutically acceptable salt or a prodrug thereof.

  本发明提供了治疗缺血介导的中枢神经系统紊乱或损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血介导的失调或损伤的组合疗法，包括向受试者施用环氧化酶-2 选择性抑制剂和促肾上腺皮质激素释放因子拮抗剂或其药学上可接受的盐或原药。
• Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20050080084A1

  公开（公告）日：2005-04-14

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a serotonin-modulating agent in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了治疗受试者中枢神经系统损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血性疾病或中枢神经系统创伤性损伤的组合疗法，该疗法包括向受试者施用血清素调节剂与环氧化酶-2 选择性抑制剂。
• Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20050080083A1

  公开（公告）日：2005-04-14

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of an angiotensin II receptor antagonist in combination with a cyclooxygenase-2 selective inhibitor.
• CANNABINOIDS AND USES THEREOF
  申请人：Corbus Pharmaceuticals, Inc.

  公开号：US20210284621A1

  公开（公告）日：2021-09-16

  The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.g., a fibrotic disease or an inflammatory disease) in a subject in need thereof.